Evaluation of the Safety of the Medical Device Simeox®

• Patient over 18, male or female.
• Patient affected by broncho-degenerative disease, chronic obstructive airway disease, cystic fibrosis, idiopathic bronchiectasis, ciliary dyskinesia and/or chronic bronchitis.
• Hospitalization for a minimum of five days or a maximum of 8 days.
• Bronchial clearance is usually productive.
• FVC and / or FEV \<85% predicted, with stable lung function.
• Agreement to participate to the study and signature of the informed consent form
• Social security coverage.

Exclusion Criteria:

• Patient infected with bacteria resistant to antibiotics.
• Bronchial clearance is not usually productive.
• Patient with contra-indication for physiotherapy bronchial clearance.
• Patient who received a lung transplant.
• Care requires more than 2 sessions of chest physiotherapy daily.
• Duration of mechanical ventilation > 8h/day.
• Patient with an episode of hemoptysis during the month before inclusion.
• Patient with an episode of pneumothorax during the last month.
• Pregnant or lactating women.
• Patient with a disability and/or unwillingness to follow protocol requirements.
• Patient participating in another clinical study or having tested an experimental drug within 30 days prior to his inclusion in the study.
• Patient ( s) with another condition which, according to the investigator , may interfere with the result or conduct of the trial and thus justify their non- inclusion in the study.